

Applicants: Michael B. Chancellor et al.
U.S. Serial No.: 09/302,896
Filing Date: April 30, 1999

Docket No.: PIT-010
(Formerly: 2710-4007US1)

IN THE SPECIFICATION:

Please amend the paragraph on page 1, lines 10-19, beneath "FIELD OF THE INVENTION" to read as follows:

B¹
The present invention relates generally to compositions and methods comprising myogenic or muscle-derived cells, including myoblasts and muscle-derived stem cells (also termed MDC herein) for tissue engineering and cell-mediated gene therapy. The invention further relates to the introduction of exogenous nucleic acids into muscle-derived cells, including myoblasts and muscle-derived stem cells, resulting in the expression of one or more gene products by the genetically engineered muscle-derived cells. Such engineered cells are then capable of producing the gene products and effecting an enhanced physiological response after administration to a recipient host, including humans.

Please amend the paragraph on page 55, lines 6-7, beneath "Example 2", to read as follows:

B²
Experiments were performed using myoblast injection into the urethral wall as a treatment for ~~urinary stress incontinence~~ stress urinary incontinence.

Please amend the paragraph on page 16, lines 14-19, to read as follows:

B³
It is another object of the present invention to provide new and effective methods and compositions for the treatment of various types of urinary incontinence, particularly ~~urinary stress incontinence~~ stress urinary incontinence, using genetically engineered muscle-derived cells in the cell-mediated delivery of exogenous genes and their encoded gene products to tissues of the urinary system, such as the urethra and bladder.